RTP Mobile Logo

Regional Meetings 2017

Second Opinion: Clinical Investigators Provide Their Perspectives on Clinical Questions and Controversies in the Diagnosis and Treatment of Ovarian Cancer

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of ovarian cancer. Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Please click here to learn more about our Gastrointestinal Cancers series or here to learn more about our Non-Small Cell Lung Cancer series.

Event Details

Schedule of Events:

Wednesday, May 24, 2017
6:00 PM Registration and dinner
6:30 PM – 7:30 PM Education program

Faculty:
Bradley J Monk, MD
Arizona Oncology
Tucson, Arizona


Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, June 21, 2017
7:30 AM – 8:30 AM Education program

Faculty:
Don S Dizon, MD
Overlook Hospital
Summit, New Jersey

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, August 1, 2017
12:00 PM – 1:00 PM Education program

Faculty:
Ursula A Matulonis, MD
Beaumont Hospital Cancer Center
Royal Oak, Michigan

Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, August 2, 2017
7:00 AM – 8:00 AM Education program


Faculty:
Don S Dizon, MD
Mayo Clinic Cancer Center
Jacksonville, Florida

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, August 3, 2017
7:00 AM – 8:00 AM Education program



Faculty:
Robert L Coleman, MD
Northside Hospital Department of Medical Education
Atlanta, Georgia

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, August 23, 2017
1:15 PM – 2:15 PM Education program


Faculty:
Ursula A Matulonis, MD
Maimonides Medical Center
Brooklyn, New York

Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, September 8, 2017
12:00 PM – 1:00 PM Education program

Faculty:
Don S Dizon, MD
Watson Clinic Cancer and Research Center
Lakeland, Florida

Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, September 14, 2017
5:30 PM Registration and dinner
6:00 PM – 7:00 PM Education program


Faculty:
Michael Birrer, MD, PhD
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, September 19, 2017
6:00 PM Registration and dinner
6:30 PM – 7:30 PM Education program

Faculty:
Bradley J Monk, MD
Ironwood Cancer & Research Center
Mesa, Arizona

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, September 20, 2017
6:00 PM Registration and dinner
6:30 PM – 7:30 PM Education program

Faculty:
Don S Dizon, MD
Allegheny General Hospital
Pittsburgh, Pennsylvania

Buffet dinner will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, September 21, 2017
5:00 PM – 6:00 PM Education program


Faculty:
Robert L Coleman, MD
Sanford Roger Maris Cancer Center
Fargo, North Dakota

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, October 4, 2017
5:30 PM Registration and dinner
6:00 PM – 7:00 PM Education program

Faculty:
Bradley J Monk, MD
New Mexico Cancer Center
Albuquerque, New Mexico

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Monday, October 23, 2017
6:00 PM – 7:00 PM Education program

Faculty:
Michael Birrer, MD, PhD
Suburban Oncology
Lawrenceville, Georgia

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, October 24, 2017
8:00 AM – 9:00 AM Education program

Faculty:
Don S Dizon, MD
Lenox Hill Hospital
New York, New York

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Agenda

Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of ovarian cancer (OC) and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Current Controversies in the Management of OC MODULE 2A: Biologic Basis for the Use of PARP Inhibitors and BRCA Testing MODULE 2B: PARP Inhibition as a Therapeutic Strategy MODULE 3: Novel Investigational Agents in OC

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Robert L Coleman, MD
Professor and Deputy Chairman
Vice Chair, Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
Houston, Texas

Don S Dizon, MD
Director, Oncology Sexual Health Clinic
Medical Gynecologic Oncology
Gillette Center for Women’s Cancers
Massachusetts General Hospital
Boston, Massachusetts

Thomas J Herzog, MD
Paul and Carolyn Flory Professor
Deputy Director, UC Cancer Institute
Vice Chair, Quality and Safety
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Bradley J Monk, MD
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona
College of Medicine - Phoenix
Creighton University
School of Medicine at St Joseph’s Hospital
Phoenix, Arizona

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Angeles Alvarez Secord, MD, MHSc
Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Duke Cancer Institute
Durham, North Carolina

Project Chair

Neil Love, MD
President
Research To Practice
Miami, Florida
 

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives:

  • Evaluate current standard therapies and emerging treatment options, and use this information to appropriately select and sequence therapeutic approaches for patients with primary and recurrent OC.
  • Describe the rationale for targeting angiogenic pathways in gynecologic cancers, and consider the role of the anti-VEGF antibody bevacizumab in the initial and long-term treatment of advanced OC.
  • Use available guidelines and consensus statements to inform the selection of validated genetic testing platforms for patients with OC, and employ the resulting information to guide treatment planning and genetic counseling for these individuals.
  • Understand the rationale for the investigation of PARP inhibitors as monotherapy for patients with BRCA mutation-positive advanced OC, and use this information to inform protocol and nonresearch treatment options for these individuals.
  • Appreciate the FDA approval of rucaparib for patients with refractory advanced OC, and safely integrate this agent into clinical management as appropriate.
  • Evaluate emerging Phase III evidence supporting the potential use of PARP inhibitor maintenance therapy for patients with recurrent, platinum-sensitive OC with and without BRCA mutations who are responding to platinum-based chemotherapy.
  • Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of investigational agents and immunotherapeutic strategies for the treatment of OC, and counsel appropriately selected patients about the availability of ongoing clinical trials.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech BioOncology, ImmunoGen Inc, Myriad Genetic Laboratories Inc and Tesaro Inc.